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.2012.01.0Abstract The purpose of this investigation was to design and develop gastroretentive dosage form
for cefuroxime axetil using ﬂoating tablet approach with various grades of hydroxypropyl methyl
cellulose. Cefuroxime axetil is known to have low bioavailability, short half-life and is absorbed
-largely from upper GIT. Sodium bicarbonate was used in the dosage form as a source of
carbon-di-oxide to maintain buoyancy. In vitro dissolution study results indicated non-Fickian
diffusion controlled drug release mechanism and was best ﬁtted into Korsmeyer–Peppas equation.
In vivo radiographic studies conducted in ﬁve healthy human volunteers for optimized formulation
indicated over 6 h retention of tablet in the stomach region. Reproducible physical parameters indi-
cated that the current formulation could be easily scaled-up.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Gastroretentive drug delivery systems are the systems which
are retained in the stomach for a longer period of time and
thereby improve the bioavailability of drugs that are preferen-
tially absorbed from upper GIT.
Reported methods for the design of gastroretentive systems
include mucoadhesion (Arora et al., 2005; Sheth and9948406955.
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03Tossounian, 1978), ﬂoatation, sedimentation (Ponchel and
Irache, 1998; Akiyama and Nagahara, 1999; Deshpande
et al., 1997), expansion (Davis et al., 1986) and modiﬁed shape
systems (Urguhart and Theeuwes, 1994). Single and multiple
system approaches have also been reported in the literature
(Fix et al., 1993).
Floating drug delivery offers a number of applications for
drugs having poor bioavailability because of narrow
absorption window in the upper part of gastrointestinal tract.
It retains the dosage form at the site of absorption and thus en-
hances the bioavailability. A gastric ﬂoating drug delivery sys-
tem (GFDDS) (Moes, 1993; Deshpande et al., 1997;
Baumgartner et al., 2000; Singh and Kim, 2000; Li et al.,
2003) can overcome at least some of these problems and is par-
ticularly useful for drugs that are primarily absorbed in the
duodenum and stomach. The GFDDS is able to prolong the
retention time of a dosage form in the stomach, thereby
improving the oral bioavailability of the drug.ier B.V. All rights reserved.
Table 1 Formulation composition of gastroretentive tablets of cefuroxime axetil.
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Cefuroxime axetil (CA) 300 300 300 300 300 300 300 300 300
HPMC (K4M) 70 80 90 – – – – – –
HPMC (K15M) – – – 40 50 60 – – –
HPMC (K100M) – – – – – – 40 50 60
Lactose monohydrate 55 45 35 85 75 65 85 75 65
Sodium bicarbonate 60 60 60 60 60 60 60 60 60
Magnesium stearate 9.7 9.7 9.7 9.7 9.7 9.7 9.7 9.7 9.7
Talc 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8
Total weight (mg) 499.5 499.5 499.5 499.5 499.5 499.5 499.5 499.5 499.5
54 G.K. Rao et al.Cefuroxime axetil (CA) is 1-acetoxyethyl ester of a
b-lactamase-stable cephalosporin, cefuroxime with a broad
spectrum of activity against Gram-positive and Gram-negative
microorganisms (McEvoy, 2003). After oral administration
CA is absorbed and rapidly hydrolyzed by esterases to produce
cefuroxime. The 1-acetoxyethylester group at 4th position of
CA ensures lipophilicity and promotes the absorption of cefur-
oxime but at the same time compromises on solubility and
hence, the prodrug shows poor and variable oral bioavailabil-
ity (Perry and Brogden, 1996). CA exists in crystalline as well
as amorphous forms; of these, latter exhibits higher bioavail-
ability owing to improved solubility. The bioavailability of
CA is variable and limited to 30% in fasted and 50% in fed
state in humans (Crisp and Clayton, 1985; Crisp et al., 1989).
A look into the existing literature unveils few approaches for
the enhancement of solubility and bioavailability for CA. Some
important ones being, formulation of bi-layered ﬂoating drug
delivery systems (Dhumal et al., 2006), ﬂoating delivery systems
(Patel and Patel, 2006), amorphous nanoparticles (Dhumal
et al., 2008) and solid dispersions (Dhumal et al., 2009).
As previously reported, CA is known to have good absorp-
tion from upper parts of GIT. Thus, retaining CA in this
region for longer time would be beneﬁcial in improving its
bioavailability.
In the present work, ﬂoating delivery system approach was
used in developing hydroxypropyl methyl cellulose (HPMC)
based dosage form. Various grades of HPMC (K4M, K15M,
K100M) were tested for their usefulness in formulating
GFDDS of CA.
2. Experimental
2.1. Materials
Cefuroxime axetil was generously gifted by Orchid Healthcare
Pvt. Ltd., India, HPMC (K4M, K15M and K100M) were pur-
chased from Sigma Aldrich. Sodium bicarbonate, magnesium
stearate, lactose and talc were purchased from S.D. Fine
Chemical Pvt. Ltd., India. All other chemicals used were of
analytical grade and were used without further puriﬁcation.
2.2. Methods
2.2.1. Drug–excipient compatibility
The infrared spectra of pure drug (CA), binary mixture of drug
and each excipient (1:1), optimized formulations and placebowere recorded between 600 and 4000 cm1 by FT-IR spec-
trometer using KBr pellet technique.
2.2.2. Preparation of tablets
The tablet excipients were chosen after comprehensive drug–
excipient interaction studies. All the tablets were prepared by
direct compression method. Formulations were prepared by
varying drug to polymer ratio and keeping other ingredients
in required quantities to make the ﬁnal weight of 499.5 mg
per tablet. Brieﬂy, preparation of tablets involved, passing all
the ingredients except magnesium stearate and talc through
sieve #40 and mixing the blend in an octagonal blender for
10 min. Magnesium stearate and talc were then passed through
sieve #60 and were used to lubricate the blend. The lubrication
was done for 5 min. The lubricated blend was compressed into
tablets using 12 mm ﬂat faced punches. The detailed composi-
tion of formulations is presented in Table 1.
2.2.3. Evaluation of tablets
The prepared tablets were evaluated for parameters like hard-
ness (Monsanto hardness tester), friability, weight variation,
thickness, water uptake, in vitro drug release, in vitro ﬂoating
lag time and total buoyancy time, in vivo buoyancy studies in
healthy human volunteers.
2.2.4. Water uptake study
The swelling behavior of dosage form can bemeasured by study-
ing its dimensional changes, weight gain or water uptake ability
(Mohammed and Khedr, 2003). The water uptake study of the
dosage form was conducted by using Type II USP dissolution
apparatus in 900 ml of distilled water which was maintained at
37 ± 0.5 Cand rotated at 50 rpm.At selected intervals, the tab-
letwaswithdrawn andweighed. Percentage swelling of the tablet
was expressed as percentage water uptake (%WU) calculated
from following equation (Chanvanpatil et al., 2006):
%WU ¼ ðWt W0Þ
W0
 100 ð1Þ
where ‘Wt’ is the weight of the swollen tablet and ‘W0’ is the
initial weight of the tablet.
2.2.5. In vitro buoyancy study
The in vitro buoyancy was determined by measuring ﬂoating
lag times and duration of buoyancy according to the method
described by Rosa et al. (1994). The tablets were placed in a
100 ml beaker containing 100 ml 0.1 N HCl. The time required
Development and in vivo evaluation of gastroretentive delivery systems 55for the tablet to rise to the surface and ﬂoat was taken as the
ﬂoating lag time. The time for which tablets kept ﬂoating was
termed as ‘buoyancy time’ of the tablets which was determined
for all the formulations.
2.2.6. In vitro release studies
The release of CA was studied using USP Type II dissolution
apparatus using 900 ml 0.1 N HCl as dissolution media main-
tained at 37 ± 0.5 C with rotation speed of 50 rpm. Aliquots
of 5 ml were collected at pre-determined time intervals and
were replenished with equivalent volume of fresh medium.
The samples were ﬁltered through a 0.45 lm ﬁlter and diluted
to a suitable concentration with 0.1 N HCl. They were ana-
lyzed by using UV–Visible double beam spectrophotometer
at 278 nm (Elico SL 164, India). The results were expressed
as mean ± S.D. (n= 3).
2.2.7. Drug release kinetics
The drug release kinetics was studied by plotting the data ob-
tained from the in vitro drug release in various kinetic models
like zero order, ﬁrst order, Higuchi, and Hixson–Crowell mod-Figure 1 FT-IR spectra of drug and excipients. I. Pure drug: (a) ce
various excipients: (b) HPMC K4M, (c) HPMC K15M, (d) HPMC K
bicarbonate. III. Optimized formulations: (i) optimized formulation (Fel. To establish the mechanism involved in drug release from
the tablets, data of percentage drug release versus log time
were plotted according to Korsmeyer–Peppas equation
(Eq. (2)). The exponent ‘n’ indicates the mechanism of drug re-
lease calculated through the slope of the straight line.
MT=M1 ¼ Ktn ð2Þ
where Mt/M1 is the fractional solute release, ‘t’ is the re-
lease time and K is a constant characteristic of the drug/
polymer system. If the exponent n= 0.45, then the drug
release follows the Fickian diffusion and if
0.45 < n< 0.85 then it is said to be non-Fickian or
anomalous release.
2.2.8. In vivo radiographic studies
For in vivo studies ethical committee clearance was obtained
from the local body to conduct trials on human volunteers.
Signed legal consent forms in native language or in English
were obtained from all the volunteers (n= 5). Placebo tablets
loaded with 300 mg barium sulfate (radio opaque agent) were
initially prepared; the in vitro buoyancy study of these tabletsfuroxime axetil (CA) pure drug. II. Binary mixtures of CA with
100, (e) lactose, (f) magnesium stearate, (g) talc and (h) sodium
2), (j) optimized formulation (F5) and (k) placebo.
Table 2 Physical parameters of gastroretentive tablets of cefuroxime axetil.
Formula Wt. variation
(mg) ± SD*
Hardness
(kg/cm2)
Diameter
(mm) ± SD*
Thickness
(mm) ± SD*
Friability
(%)
Drug content
(%) ± SD*
Floating lag
time (min)
Buoyancy
time (h)
Drug release (t12)
(%) ± SD^
F1 505 ± 8.30 7.5 12 ± 0.02 4.54 ± 0.02 0.34 98.91 ± 2.80 2.03 >12 99.56 ± 0.55
F2 515 ± 3.80 8.0 12 ± 0.02 4.61 ± 0.02 0.45 98.46 ± 3.20 2.08 >12 97.97 ± 1.85
F3 501 ± 4.90 7.2 12 ± 0.02 4.36 ± 0.02 0.25 97.41 ± 2.10 2.20 >12 80.05 ± 3.31
F4 510 ± 5.30 7.0 12 ± 0.02 4.64 ± 0.02 0.39 96.54 ± 2.60 2.13 >12 99.96 ± 1.82
F5 505 ± 2.30 6.0 12 ± 0.02 4.64 ± 0.02 0.48 96.33 ± 2.50 2.26 >12 97.98 ± 1.24
F6 503 ± 5.40 7.2 12 ± 0.02 4.52 ± 0.02 0.45 96.54 ± 1.80 2.43 >12 89.20 ± 1.18
F7 502 ± 3.20 7.4 12 ± 0.02 4.79 ± 0.02 0.27 96.33 ± 2.30 2.53 >12 70.98 ± 1.46
F8 508 ± 8.20 7.0 12 ± 0.02 4.21 ± 0.02 0.55 97.41 ± 2.10 2.76 >12 66.65 ± 1.77
F9 507 ± 4.30 7.4 12 ± 0.02 4.44 ± 0.02 0.38 95.41 ± 1.80 2.91 >12 58.53 ± 2.66
The bold font indicates that F2 and F5 are optimized formulations form the lot.
* SD = standard deviation (n= 3).
^ t12 – %Drug release at 12 h.
56 G.K. Rao et al.showed signiﬁcant increase in lag time which was attributed to
high molecular weight of barium sulfate. Hence, it was excogi-
tated to replace half of the barium sulfate (150 mg) with CA.
Tablets with 150 mg barium sulfate and 150 mg CA were cho-
sen for in vivo radiographic studies.
For this study, human subjects were fasted overnight and
were only allowed free access to water ad libitum. They were
orally administered one tablet each with 250 ml of water.
Radio graphs were obtained using X-ray equipment after time
intervals of 0.5, 1.5, 4 and 6 h. During the period of study, vol-
unteers were allowed free access to only water. (Machida et al.,
1989; Iannucelli et al., 1998).Figure 2 Percentage swelling of the different grades of HPMC
formulations.3. Results and discussion
3.1. FT-IR studies for drug–excipient compatibility
The IR spectra of CA showed the characteristic absorption
peaks at 1661, 1787, 1733 cm1 indicating the presence of car-
bonyl C‚O stretching. Strong absorption band at 3484 cm1
represented primary amine N–H stretching and characteristic
band at 1212 cm1 represented C‚H stretching. The IR spec-
tra of physical mixture also showed the above mentioned
bands of CA of respective functional groups. From the data,
it was concluded that there was no interaction with the excip-
ients used in the formulation. The FT-IR spectra of CA, bin-
ary mixture (1:1) of CA with each excipient, optimized
formulations and placebo are shown in Fig. 1.
3.2. Physical properties of the compressed ﬂoating tablet systems
The ﬂoating tablets of cefuroxime axetil were prepared by di-
rect compression technique using HPMC (K4M, K15M, and
K100M), lactose, sodium bicarbonate, along with magnesium
stearate and talc. The results of the physical characteristics of
ﬂoating tablets are shown in Table 2. The physical evaluation
of the tablets revealed uniform thickness and weight for all the
tablets (evident from low% RSD values). The hardness values
between 6 and 8 kg/cm2 and low friability values (below
0.45%) across all formulations indicated that the tablets had
sufﬁcient mechanical strength. The drug content uniformity
studies revealed that drug content between 96.33 ± 2.3%
and 98.91 ± 2.8% is acceptable.3.3. Water uptake studies
Swelling of tablets is a direct indication of amount of water up-
take by the tablets. Water uptake studies showed that formu-
lation with high percentage of HPMC imbibed more water
and were swollen to greater extent than formulation with
low percentage of HPMC.
The percentage swelling obtained from the water uptake
studies of all the formulations is shown in Fig. 2. The formu-
lations with HPMC K4M, HPMC K15M and K100M showed
signiﬁcant swelling and good tablet integrity. The change in so-
dium bicarbonate concentration has not shown any effect on
swelling of the tablet. The formulations with HPMC K100M
showed higher swelling compared to formulations with
K4M, K15M. The swelling index of the tablets increases with
an increase in the polymer viscosity grades.
3.4. In vitro lag time measurement
From the lag time measurement study, it was evident that for
all the formulations, the lag time was between 2 and 3 min.
This concords with the earlier reported work (Patel and Patel,
2006) where the average lag time was below 3 min. The bilay-
ered tablet approach for CA, as reported by Dhumal et al.,
2006, showed variable lag time ranging from 12 to 35 min.
Figure 3 In vitro buoyancy study of optimized formulation (F2).
(a) 
(b) 
(c) 
Figure 4 Drug release proﬁles: (a) drug release proﬁles of
cefuroxime axetil ﬂoating tablets with HPMC K4M (F1–F3), (b)
HPMC K15M (F4–F6) and (c) HPMC K100M (F7–F9).
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tablets
The concentration of gas generating agent sodium bicarbonate
was found to be critical factor that inﬂuenced buoyancy of tab-
lets. Sodium bicarbonate released CO2 gas that was trapped
into the polymeric matrix of HPMC that made the tablets
buoyant. Various concentrations of sodium bicarbonate rang-
ing from 10% to 16% of tablet weight were used.
From the results, it was concluded that with the increasing
concentration of sodium bicarbonate, the lag time decreased.
A concentration of 12% w/w sodium bicarbonate was found
to be optimal that resulted in tablets having lag time <3 min
and ﬂoating time of over 12 h. Similar conclusions were also
drawn by other researchers working on ﬂoating delivery sys-
tems of CA. In both the reported works, optimum concentra-
tion of sodium bicarbonate was found to be around 10% w/w
of the tablet weight (Dhumal et al., 2006; Patel and Patel,
2006) which is slightly lower than our optimal concentration.
It was interesting to note that the grade of HPMC used in
the formulations has impact on lag of the tablets. With the
increasing molecular weight of HPMC, the viscosities of the
gel matrix around the tablet also increased which in turn in-
creased the lag time. The lag time for HPMC K100M tablets
was slightly higher compared to HPMC K4M and HPMC
K15M tablets. This may be attributed to the increased density
of tablets with increasing molecular weight of HPMC.
3.5. In vitro buoyancy time measurement
Buoyancy time was deﬁned as the time period for which tablets
kept ﬂoating on the surface of media before sinking completely
to the bottom.
From the buoyancy studies (as indicated in Table 2 and
Fig. 3), it was evident that all the formulations showed similar
buoyancy times (over 12 h). Hence, the differentiating factor to
choose the optimal formulation was taken as the drug release
criterion in 12 h buoyancy period.3.6. In vitro drug release studies
A rigorous study of dissolution proﬁle for all the formulations
gave an insight into the effect of polymeric ﬁllers and gas gen-
erating agent on release proﬁle of the formulations.
From the release proﬁles, it was observed that the variation
in grade of polymer and its concentrations from F1 to F9 had
variable effect on drug release. These data were illustrated in
Fig. 4a–c. The effects of HPMC K4M, K15M and K100M
could be observed at constant sodium bicarbonate level. The
presence of HPMC K4M increased the release rate and extent
compared to HPMC K15M and K100M.
Similar conclusions were also drawn by earlier workers who
worked in the development of ﬂoating delivery systems of CA
(Dhumal et al., 2006; Patel and Patel, 2006).
Similar proﬁles are observed, though, to a much smaller ex-
tent (due to closeness of the formulations) in case of the opti-
mized formulations F2, F5 (Fig. 4a and b). These ﬁndings can
be explained in the light of difference in molecular weight of
the two varieties of HPMC.
Figure 5 In vivo radiographic images of tablets at 0.5, 1.5, 4 and 6 h.
Table 3 Drug release kinetics of optimized formulations.
S. no. Formulation code Zero order First order Higuchi Korsmeyer and Peppas Peppas (n) Mechanism of drug release
1 F2 0.974 0.684 0.898 0.994 0.55 Non-Fickian
2 F5 0.962 0.503 0.933 0.915 0.75 Non-Fickian
58 G.K. Rao et al.HPMC K15M with higher molecular weight, forms gel of
higher viscosity (15,000 cps) compared to HPMC K4M (nom-
inal viscosity 4000 cps). However, due to higher molecular
weight, the polymer chains are bulkier in K15M leading to less
ﬂexibility and hence more time for polymer–solvent interaction
and polymer chain relaxation. Consequently, the polymer
chain unwinding is delayed in case of HPMC K15M compared
to HPMC K4M, thereby leading to reduced gelling rate for the
former variety.
As a result of this, the effective diffusion rate of drug
through matrices containing higher percentage of HPMC
K4M is more leading to higher dissolution rates from these
tablets.
Formulations F2 and F5 were chosen as optimal based on
their ability to sustain drug release up to 12 h period as evident
from Table 2 and Fig. 4.
Though formulations F1 and F4 showed good release char-
acteristics, more than 95% of drug was released before 12 h (at
about 10 h) period which is undesirable, while, formulations F3,
F6–F9 showed less than 90% drug release even after 12 hperiod leading to the loss of remaining drug embedded in the
matrix.
By comparing three different grades of HPMC (K4M,
K15M and K100M), we concluded that low-viscosity grade
HPMC K4M provided better release characteristics and
showed good in vitro buoyancy. From the results, it was also
concluded that with the increase in molecular weight of
HPMC, the drug release could be retarded greatly.3.7. Drug release kinetics
The mechanism of release for the above formulations was
determined by ﬁnding the R2 value for each kinetic model viz.
zero-order, ﬁrst-order, Higuchi, and Korsmeyer–Peppas corre-
sponding to the release data of each formulation. For most of
the formulations the R2 value of Korsmeyer–Peppas and
zero-order model is very near to one than the R2 values of other
kinetic models. Thus, it can be said that the drug release follows
Korsmeyer–Peppas and zero-order model mechanism.
Development and in vivo evaluation of gastroretentive delivery systems 59The ‘n’ values of Korsmeyer–Peppas model for the best
formulations were in the range of 0.45–0.85. Therefore, the
most probable mechanism of release was non-Fickian
diffusion or anomalous diffusion. All the values are shown
in Table 3.
3.8. In vivo radiographic studies
In vivo studies were conducted on healthy human volunteers to
ﬁnd the gastric residence time of the tablet. The studies were
based on X-ray radiography. Both the optimized formulations
(F2 and F5) were selected for the study. However, during the
course of study, formulation F5 could not remain buoyant
after 4 h period (data not shown). Hence, the study was contin-
ued with volunteers ingested with formulation F2 up to 6 h.
The position of tablet at the end of various time intervals (indi-
cated by tiny arrows) in Fig. 5 showed that the selected formu-
lation (F2) was retained in the upper part of GIT for well over
6 h.
Statistical treatment of the data for formulation F2 did not
show any signiﬁcant difference (p< 0.05) between the volun-
teers (n= 5).4. Conclusion
From the data obtained, it can be concluded that hydrodynam-
ically balanced tablet of cephalosporin antibacterial drug CA
can be formulated as an approach to increase gastric residence
time and thereby improve its bioavailability. The derivatives
of swellable polymer HPMC showed better control over the
drug release. Formulated tablets gave satisfactory results for
various physicochemical evaluations for tablets like tablet
dimensions, hardness, weight variation, ﬂoating lag time, total
ﬂoating time, content uniformity and in vitro drug release. For-
mulations F2 and F5 gave better sustained drug release in com-
parison to other formulations. These formulations best ﬁtted to
Korsmeyer–Peppasmodel and zero-order kinetics. In vivo radio-
graphic studies indicated that tablets remained in the stomach
for about 6 h (for formulation F2), which indicates the increase
in the gastric residence time due to ﬂoating and swelling
principle.Acknowledgments
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